In vitro model of neurotoxicity of Aβ 1-42 and neuroprotection by a pentapeptide:: irreversible events during the first hour

被引:66
作者
Datki, Z
Papp, R
Zádori, D
Soós, K
Fülöp, L
Juhász, A
Laskay, G
Hetényi, C
Mihalik, E
Zarándi, M
Penke, B
机构
[1] Univ Szeged, Dept Med Chem, H-6720 Szeged, Hungary
[2] Univ Szeged, Dept Psychiat, H-6720 Szeged, Hungary
[3] Univ Szeged, Dept Bot, H-6720 Szeged, Hungary
[4] Eotvos Lorand Univ, Dept Biochem, Budapest, Hungary
[5] Hungarian Acad Sci, Prot Chem Res Grp, Szeged, Hungary
关键词
beta-amyloid; neurite degeneration; neuroblastoma cells; aggregation; neuroprotection;
D O I
10.1016/j.nbd.2004.08.007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The cell biology of Alzheimer's disease (AD) is characterized mainly by the neurodegeneration caused by the beta-amyloid (Abeta) peptides and by the formation of neurofibrillary tangles. The initial events of neurodegeneration in the brain tissue include synaptic dysfunction and axonopathy. Abeta-induced axonopathy and neurite degeneration were studied in vitro on differentiated human-derived neurotypic SH-SY5Y cells. Different methods were used to investigate the mechanism of action of aggregated Abeta on neuroblastoma cells. Abeta 1-42 aggregated for 1 h induced irreversible changes in the neurite morphology. Change of tau hyperphosphorylation and cell viability (cytoplasmic redox state and active membrane uptake) was irreversible during the first hour after the addition of Abeta 1-42 to the cells. These rapid events indicate that A might induce neurodegeneration even at an early stage of A cell contact. A novel pentapeptide LPYFD-amide, an analog of Soto's LPFFD, significantly decreased neurite degeneration, tau aggregation, and cell viability reduction induced by Abeta 1-42. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:507 / 515
页数:9
相关论文
共 33 条
[1]   Cytoskeletal mechanisms of neuronal degeneration [J].
Brandt, R .
CELL AND TISSUE RESEARCH, 2001, 305 (02) :255-265
[2]   A model for structure-dependent binding of Congo red to Alzheimer β-amyloid fibrils [J].
Carter, DB ;
Chou, KC .
NEUROBIOLOGY OF AGING, 1998, 19 (01) :37-40
[3]   Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells [J].
Datki, Z ;
Juhász, A ;
Gálfi, M ;
Soós, K ;
Papp, R ;
Zádori, D ;
Penke, B .
BRAIN RESEARCH BULLETIN, 2003, 62 (03) :223-229
[4]   Aberrant activation of focal adhesion proteins mediates fibrillar amyloid β-induced neuronal dystrophy [J].
Grace, EA ;
Busciglio, J .
JOURNAL OF NEUROSCIENCE, 2003, 23 (02) :493-502
[5]   Characterization of neuronal dystrophy induced by fibrillar amyloid β:: Implications for Alzheimer's disease [J].
Grace, EA ;
Rabiner, CA ;
Busciglio, J .
NEUROSCIENCE, 2002, 114 (01) :265-273
[6]   Neurofibrillary degeneration of the Alzheimer-type:: an alternate pathway to neuronal apoptosis? [J].
Hamdane, M ;
Delobel, P ;
Sambo, AV ;
Smet, C ;
Bégard, S ;
Violleau, A ;
Landrieu, I ;
Delacourte, A ;
Lippens, G ;
Flament, S ;
Buée, L .
BIOCHEMICAL PHARMACOLOGY, 2003, 66 (08) :1619-1625
[7]   Pentapeptide amides interfere with the aggregation of β-amyloid peptide of Alzheimer's disease [J].
Hetényi, C ;
Szabó, Z ;
Klement, T ;
Datki, Z ;
Körtvélyesi, T ;
Zarándi, M ;
Penke, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 292 (04) :931-936
[8]   Mapping of possible binding sequences of two beta-sheet breaker peptides on beta amyloid peptide of Alzheimer's disease [J].
Hetényi, C ;
Körtvélyesi, T ;
Penke, B .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (05) :1587-1593
[9]   Tau and axonopathy in neurodegenerative disorders [J].
Higuchi, M ;
Lee, VMY ;
Trojanowski, JQ .
NEUROMOLECULAR MEDICINE, 2002, 2 (02) :131-150
[10]   Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease [J].
Ishiguro, K ;
Ohno, H ;
Arai, H ;
Yamaguchi, H ;
Urakami, K ;
Park, JM ;
Sato, K ;
Kohno, H ;
Imahori, K .
NEUROSCIENCE LETTERS, 1999, 270 (02) :91-94